Zacks Research Issues Pessimistic Estimate for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research note issued on Wednesday, August 13th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $5.51 per share for the quarter, down from their prior forecast of $5.52. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.47 EPS, FY2025 earnings at $22.48 EPS, Q1 2026 earnings at $5.51 EPS, Q3 2026 earnings at $6.19 EPS, Q4 2026 earnings at $6.50 EPS and Q2 2027 earnings at $7.10 EPS.

Other equities research analysts also recently issued research reports about the company. UBS Group increased their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Raymond James Financial reissued an “outperform” rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. HSBC restated a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $485.62 on Thursday. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a market capitalization of $183.38 billion, a P/E ratio of 28.09, a PEG ratio of 2.59 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm’s 50 day moving average is $433.08 and its 200 day moving average is $461.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.37 EPS.

Institutional Trading of Thermo Fisher Scientific

Institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $2,264,615,000. GAMMA Investing LLC increased its position in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Soundwatch Capital LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $807,713,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares in the last quarter. Finally, Flossbach Von Storch SE increased its position in shares of Thermo Fisher Scientific by 93.0% during the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after buying an additional 1,314,182 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.